Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01427517 · ClinicalTrials.gov registry record · Phase 1
Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01427517 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 9 participants.
The verdict
NCT01427517, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The investigators are interested in determining if the investigators are able to detect changes in brain chemistry using Magnetic Resonance Spectroscopy (MRS) in individuals with Parkinson's disease (PD), those with Gaucher's disease (GD), and those without neurological disorders (healthy controls) when they are given the antioxidant N-acetylcysteine (NAC). This study will combine information from a medical history, a physical examination and disease rating scales with results obtained using MRS brain scans and pharmacokinetic studies from blood samples. This research will require 1 visit that will require about 4 to 5 hours of time. During this study, participants will provide their medical history, be examined and undergo a rating scale for about one hour; the brain scan and pharmacokinetic studies will require 1.5-2 hours of time; in total the study will take about 4-5 hours.
Interventions
- DRUG N-acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01427517
The ClinicalTrials.gov registry entry for NCT01427517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-acetylcysteine is the first listed.
NCT01427517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01427517 about?
NCT01427517 is a clinical study titled "Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease". The investigators are interested in determining if the investigators are able to detect changes in brain chemistry using Magnetic Resonance Spectroscopy (MRS) in individuals with Parkinson's disease (PD), those with Gaucher's disease (GD), and those without neurological disorders (healthy controls) ...
What is the current status of trial NCT01427517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2011-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01427517?
The interventions under investigation include: N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT01427517?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.